Abstract | Diarthrodial joints are well suited to intra-articular injection, and the local delivery of therapeutics in this fashion brings several potential advantages to the treatment of a wide range of arthropathies. Possible benefits over systemic delivery include increased bioavailability, reduced systemic exposure, fewer adverse events, and lower total drug costs. Nevertheless, intra-articular therapy is challenging because of the rapid egress of injected materials from the joint space; this elimination is true of both small molecules, which exit via synovial capillaries, and of macromolecules, which are cleared by the lymphatic system. In general, soluble materials have an intra-articular dwell time measured only in hours. Corticosteroids and hyaluronate preparations constitute the mainstay of FDA-approved intra-articular therapeutics. Recombinant proteins, autologous blood products and analgesics have also found clinical use via intra-articular delivery. Several alternative approaches, such as local delivery of cell and gene therapy, as well as the use of microparticles, liposomes, and modified drugs, are in various stages of preclinical development.
Introduction
For a drug with a direct mode of action, local administration offers several advantages over systemic delivery, including increased bioavailability, reduced systemic exposure, fewer off-target effects and adverse events, and lower total drug cost. Being discrete cavities, most diarthrodial joints are well suited to local drug delivery via intra-articular injection. Osteoarthritis (OA), which affects individual joints, and polyarticular inflammatory pathologies, including rheumatoid arthritis (RA) and gout, have high incidence and long-term therapeutic need; moreover, current treatment options are inadequate for many patients. Thus, tremendous interest has been generated in achieving successful localization of therapeutics at the pathological site, to maximize efficacy and reduce drug cost. Most common disorders of diarthrodial joints-with RA the exception-are not accompanied by clinically significant extra-articular manifestations, which makes the prospect of local therapy particularly appealing. Reflecting the growing interest in this field, the second International Symposium on Intra-Articular Treatment was held in Barcelona in October 2013. 1 This Review discusses therapeutics that can be comfortably introduced into the joint in an outpatient setting via a small-gauge needle. Arthroscopy and other surgical procedures are, therefore, excluded. First, we describe how the biology of the joint controls the entry and clearance of exogenous molecules. Next, we outline current uses of intra-articular therapy in rheumatology and orthopaedics. Finally, we consider the development of emerging strategies such as drug-delivery particles, gene transfer and cell-based therapies.
The pharmacokinetics of the joint
The joint-space 'dwell time' of a therapeutic agent is influenced by the rate at which the molecule reaches and is cleared from the synovial fluid. The former parameter depends on the size and route of administration of the drug, whereas the rate of efflux of a soluble agent is largely independent of these properties ( Figure 1 ). Systemically delivered, soluble substances enter the joint space via the capillary network of the subsynovium, which is highly vascularized; small molecules also leave via the vasculature, whereas larger substances such as proteins exit via the lymphatic system. 2 Drug delivery to cartilage For certain indications, it is necessary to deliver therapeutics to cartilage. Because cartilage is avascular, it is inefficiently targeted by systemic delivery of drugs, which must first reach the synovial fluid and then diffuse through the cartilagenous extracellular matrix (ECM). Unless damaged, this matrix is highly anionic and increasingly impermeable to molecules much greater than the size of albumin (~67 kDa), depending upon their charge and conformation. 3 Intra-articular therapy improves delivery to cartilage and can therefore increase thera peutic efficacy, but in doing so it exposes chondrocytes to higher concentrations of drugs. In developing intra-articular therapeutics, therefore, investigators must be aware of the potential for exposing previously unrecog nized chondrotoxicity.
Joint-space entry is size-dependent
To enter the joint space from the synovial circulation, solutes need to pass through two layers of resistance in series: the capillary wall and the ECM of the synovial intima. 4 The endothelial lining of the subsynovial capillaries is fenestrated, with the fenestrations orientated towards the joint space; this orientation facilitates the directed exit of solutes from these capillaries. Because the synovium has no basement membrane to impede molecular transit, 5 small molecules pass freely through the vascular endothelium, and the major determinant of their entry into the joint space is their rate of diffusion through the synovial interstitium. With this entry route being dependent on the small pores of the capillary endothelium and the tight spaces of the interstitial matrix, unimpeded transport through passive diffusion occurs only for small molecular weight (MW) compounds, typically <10 kDa.
For larger molecules, the endothelial lining imposes a size-dependent sieving effect on the rate of passage ( Figure 2 ). For example, the concentration ratio of normal synovial fluid:serum for albumin is ~0.40; for the much larger molecules α2-macroglobulin and IgG this ratio drops to 0.03-0.05. 6 Fibrinogen, with a MW of 340 kDa, is rarely found in synovial fluid in the absence of inflammation, probably because of its very high Stokes radius (that is, hydro dynamic radius). 6 Inflammation increases synovial permeability Synovial inflammation is a key feature of many joint pathologies; most notably observed in RA and following joint injury, it is also present in OA. 7 In an inflamed joint, capillary permeability increases, thereby enhancing the entry of macromolecules into the joint space. Evidence of this effect can be found in the protein content of synovial fluid from patients with RA, which is increased in comparison with healthy controls, as well as notable increases in the proportion of large to small molecular components in RA samples. 6, 8 Macromolecules have short dwell time Although entry of macromolecules into joints is constrained, their removal from joints occurs via the lymphatic system in a fashion that, unlike their entry, is independent of size ( Figure 1 ). The rate of removal of macro molecules Key points ■ Getting therapeutics into joints in a targeted and sustained fashion is difficult ■ Intra-articular injection solves the delivery problem and brings several additional advantages over systemic administration, including increased bioavailability, reduced systemic exposure, fewer off-target effects and lower costs ■ Soluble drugs exit joints rapidly, via the capillaries (in the case of small molecules) and lymphatic system (for macromolecules) ■ Strategies for extending the intra-articular half-lives of therapeutics include the use of small particles, drug modification and gene transfer ■ Delivery of hyaluronate and corticosteroids accounts for the majority of intraarticular injections; additional therapeutics include recombinant proteins, autologous blood products and analgesics ■ Clinical trials involving the intra-articular injection of mesenchymal stem cells have multiplied enormously in recent years from the joint is increased in patients with RA, reflecting enhanced drainage from the joint space due to greater synovial lymph flow. 9 Because lymphatic drainage is highly efficient, the intraarticular dwell time of proteins in joints is typically a few hours or less. This timescale presents obvious problems when attempting to treat chronic joint disorders with large molecules. Although intra-articular injection can circumvent the entry restrictions imposed by synovial sieving (Figure 1) , it cannot avoid rapid lymphatic clearance of a therapeutic agent. The need to increase intra-articular dwell time was a major reason why local gene delivery to joints was suggested as a therapeutic strategy. 10 Similar time constraints exist for small molecules, which rapidly diffuse from the joint via the synovial capil laries. Larsen et al. 11 have tabulated the half-lives of various substances within the joints of experimental animals as well as within healthy and arthritic human joints. The values reported range from 0.23 h for acridine orange (MW 370 Da) to 1.23-13.1 h for albumin and 26.3 h for hyaluronic acid (MW 3 × 10 6 Da). Intra-joint half-lives of NSAIDs and soluble steroids cluster at around 1-4 h. 11 These values illustrate the challenges facing in tra-articular therapy, especially for chronic conditions.
Intra-articular injection
Pros and cons versus systemic delivery Although various prodrug 12 and particle-based 13 strategies for targeting drugs to inflamed joints through the systemic circulation are in development, intra-articular injection remains the method of choice for local therapeutic delivery. This route of administration overcomes concerns about the extent of bioavailability, unknown or uncontrollable drug dosing, the effects of drug binding to systemic molecules, and other drug modifications that can limit the efficacy of a substance administered via systemic delivery. Moreover, it eliminates many patient compliance issues.
Nevertheless, in many countries, intra-articular injections are performed almost exclusively by rheumatologists and orthopaedists; this requirement for specialist time is limiting when repetitive, serial injections are neces sary. The exclusion of the general practitioner places intra-articular delivery at a logistical disadvantage compared with oral and self-administered, subcutaneous administration. However, the development of technologies such as fluoroscopy and ultrasonography to ensure accuracy could expand the use of intra-articular injection to a wider spectrum of physicians.
Clinical history
Clinical use of intra-articular injections dates back to the 1930s when formalin, glycerin, lipodol, lactic acid and petroleum jelly were among the first substances injected into patients with arthritis.
14 Widespread and persistent use of the technique began in the 1950s when intraarticular injections of corticosteroids became common for treating patients with RA. 15 More recently, the use of intraarticular injections has expanded greatly with the approval of therapeutics based on hyaluronate for the treatment of OA (discussed later in this manuscript).
Delivery and adverse events
Accuracy of injection is an issue, even for large, accessible joints such as the knee where as many as 50% of intended intra-articular injections by experienced physicians can end up in extra-articular locations. 16, 17 Nevertheless, Simkin 18 has argued that, because the synovial fluid is contiguous with the interstitial fluid of the synovium, any injection within the joint capsule is close enough to the target site. Accu racy is improved by fluoroscopic and ultrasound guidance techniques, and these tools are particularly valuable for treating joints, such as the hip, that are difficult to access.
Other than injection-site reactions in certain individuals, little morbidity is associated with intra-articular injection of corticosteroids or hyaluronate, the main concern being infection. Incidences of infection of 1 in 3,000 to 1 in 50,000 have been reported in the literature. 19 Although these rates are low, the increased cumulative risk of infection with repeat administration and concern about possible adverse effects of corticosteroids on cartilage create reluctance to inject joints too frequently. No rigid guidelines on this matter exist, but most practitioners are reluctant to inject a joint more than once every 3-6 months, unless delivering agents based on hy aluronate, which can require multiple injections.
Intra-articular therapeutics
Corticosteroids A long history of intra-articular corticosteroid use exists for patients with RA. 15 Although the introduction of TNF antagonists has reduced the need for intra-articular cortico steroids in this disease, they are still administered to individual symptomatic joints that fail to respond to systemically delivered drugs.
Joint-space kinetics
Corticosteroids are highly hydrophobic, small (<700 Da) hydrocarbons that can be transported into the joint space after systemic administration through trans-capillary diffusion, although resulting bioavailability in the synovial fluid is much reduced in comparison with the systemic compound. Thus, one motivation for developing intra-articular delivery of corticosteroids has been to increase effective dosing. Besides increasing the rate of entry to the joint, intra-articular injection also enables delivery of modified molecules that would be incompatible with systemic delivery-such modifications can increase the intra-joint retention of corticosteroid formulations. Drug clearance is thus reduced through the use of excipients (for example, polyethylene glycol [PEG] , dextran or p olysorbate-based suspension) that promote retention of the drug in an aqueous solution, or salts that promote retention of the steroid in a crystalline form over long periods of time. In this manner, the drugs are complexed with salts or polymers and suspended in aqueous solutions that act to sequester the drug from the synovial fluid and delay clearance from the joint space. 20, 21 Nevertheless, the intra-articular halflives achieved for corticosteroids have rarely been found to exceed 12 h, owing to the very low molecular weights of these compounds. 21 Roles in rheumatology and orthopaedics Intra-articular corticosteroids are a mainstay of therapy in OA 22 and are typically reserved for joints with refractory pain and/or effusion. Although pain and other symptoms are reduced for up to 4 weeks following injection, 22 there is concern that prolonged exposure to steroids might adversely affect articular cartilage and thus accelerate the progress of the disease. For this reason, many physicians limit the use of corticosteroids to 3-4 intra-articular in jections annually into any given joint with OA. Figure 2 ). Small molecules also enter via the capillaries, but the major resistance to their entry is provided by the ECM of the synovial interstitium. Intra-articular injection bypasses both of these constraints to entry. However, both large and small molecules rapidly exit the joint, via the lymphatic system and small blood vessels, respectively. Abbreviations: ECM, extracellular matrix; IA, intra-articular.
Size-independent
Corticosteroids are also administered for gout, and for treating many other circumstances in which the joint is painful or inflamed. Their use after injury to the joint to prevent the development of post-traumatic OA might also be possible; the results of a cartilage-explant study published in 2011 indicate that short-term glucocorticoid therapy prevents the catabolic consequences of mechanic al injury and proinflammatory cytokines. 23 Formulation and use A number of different corticosteroid formulations are available for intra-articular injection (Box 1). Few studies have compared their effectiveness; those that have done so suggest that triamcinolone hexacetonide might be of greater benefit than other preparations in RA, 24, 25 juvenile idiopathic arthritis 26 and in OA, 27 perhaps because it is least soluble.
Several studies have suggested that intra-articular glucocorticoid injection for knee synovitis has a better outcome in resting patients than in mobile patients. Nevertheless, on the basis of objective measures of serum levels of triamcinolone hexacetonide, cortisol and adreno corticotropic hormone, immobilization does not seem to retard glucocorticoid resorption after intra-articular administration. 28 Hyaluronate Intra-articular administration of the ECM component hyaluronate is very common for the treatment of pain in joints with OA that has not responded to NSAIDs or analge sics such as acetaminophen. Seven different hyal uronate preparations have been approved by the FDA for injection into the knee (Box 1); a growing literature also investigates their use in other joints such as the hip, sh oulder, facet joint and the small joints of the hands and feet. 29 
Joint-space kinetics
Unmodified hyaluronate reportedly resides within the joint space for 12-24 h following intra-articular delivery. 30 Historically considered to be the main lubricant of the joint (before the discovery of lubricin, see below), hyaluronate is believed to act as a viscosupplement following intra-articular injection, replacing or supplementing the endogenous molecule. 31 As such, its longevity and persistence within the joint space are crucial to its function, which depends on its physical presence. Thus, investigators are developing very high molecular weight, or crosslinked, hyaluronate preparations that can reportedly contribute to intra-articular half-lives exceeding 48 h in animal studies; 32 crosslinked preparations are also in clinical use (Box 1).
Clinical performance and development
Given the prevalence of OA and the current lack of diseasemodifying therapies, intra-articular injections of hyaluronate are widely used and represent one of the most common reasons for intra-articular injection. However, opinion remains divided on their efficacy and considerable divergence is reported in the literature, including in the contrasting results of meta-analyses. 33, 34 Potentially, improved understanding of how ECM molecules such as hyaluronate influence the intra-articular pathophysiology of the joint in OA will lead to more effective alternatives. Indeed, interest is high in the possible intra-articular application of another lubricating macromolecule, lubricin, for the treatment of OA. 35 Lubricin, also known as proteoglycan 4, is thought to be particularly important for cartilage-on-cartilage lubrication and to be more effective than hyaluronate in this regard. Its absence in humans with the disease camptodactylyl-arthropathy-coxa varapericarditis syndrome 36 or knockout mice 37 leads to cartilage degeneration. Intra-articular injection of lubricin prevents the development of post-traumatic OA in rats. 38 
Biologic agents

Joint-space kinetics of proteins
The success of infliximab, etanercept, adalimumab and other anti-TNF agents as systemic treatments for RA has 
Various analgesics *FDA approved.
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led to their intra-articular use in individual joints that do not respond to systemic therapy. 39 Other recombinant proteins, such as the IL-1 receptor antagonist anakinra and the anti-IL-1β monoclonal antibody canakinumab have followed suit and are being trialled as joint injections (Table 1) . These agents are typically soluble proteins with kinetics of joint clearance that, in line with the discussion in the "Pharmacokinetics of the joint" section, can be expected to generate half-lives of approximately 2-4 h.
Systemic versus intra-articular anti-TNF agents
Clinical trials of joint injections of the TNF antagonist etanercept have been pursued for the treatment of both RA and refractory knee joint synovitis (Table 1) . Similarly, intra-articular delivery of infliximab for the treatment of OA and spondyloarthritis has been compared with intravenous delivery of the biologic agent or corticosteroid. Although no randomized controlled trial has been published, anecdotal reports indicate outcomes of success in treating spondyloarthritis, RA and OA. [40] [41] [42] However, intra-articular delivery of proteinaceous anti-TNF agents has not become a mainstay of clinical care.
Clinical progress with other proteins
Recombinant interleukin-1 receptor antagonist (rIL-1Ra; anakinra) has been evaluated as an intra-articular treatment for OA. Despite the encouraging results of an openlabel pilot study, 43 a subsequent phase II study showed only short-term benefit. 44 This finding might reflect the rapid egress of rIL-1Ra, a 17 kDa protein, from the joint. Nevertheless, a single, intra-articular injection of anakinra immediately after injury prevented post-traumatic OA in a mouse fracture model of the disease. 45 Of interest, the same dose administered daily for 1 month by a subcutaneous osmotic pump had no effect. In a phase I clinical study, intra-articular injection of anakinra improved short-term outcomes after rupture of the anterior cruciate ligament. 46 As for TNF antagonists and any new indication, the time, amount and dosing to achieve a therapeutic concentration in the joint space, albeit for a short duration, are critical but unknown variables.
Intra-articular delivery of bone morphogenetic protein 7 (BMP7) showed promising results in a phase I clinical study in patients with OA of the knee, 47,48 but data from the subsequent phase II trial have not yet been published. 49 Fibroblast growth factor 18 (FGF18) and canakinumab are also in current clinical trials testing their efficacy as intra-articular treatments for OA (Table 1) .
Autologous blood products
Platelet-rich plasma (PRP) is widely used by the orthopaedic community as a treatment for a variety of musculoskeletal problems, including OA, despite scant solid evidence to commend this approach. 50 A few case reports and small clinical series in which PRP has been injected into joints with OA have been published; however, the results are equivocal and much more research is needed. 51 Clinical experiences are difficult to compare, because different preparations of PRP have different compositions and variable effects on inflammation. 52 A concentrated PRP product known as Autologous Protein Solution is being evaluated in patients with OA.
53,54
Autologous conditioned serum is obtained from incubated blood and injected into joints with OA or other painful conditions. Whole blood is incubated with m edical-grade, etched glass beads that induce the synthesis of anti-inflammatory molecules, including IL-1Ra. 54, 55 After filtration, the conditioned serum is injected into the joint. Apart from rare cases of acute inflammation after intra-articular administration of this complex preparation, the overall incidence of complications seems to be low. 56 A randomized controlled clinical trial in 376 patients with knee OA demonstrated a therapeutic effect superior to that achieved with the injection of saline or hyaluronic acid. 57 
Analgesics
Local anaesthetics have FDA approval as injections for the production of local or regional anaesthesia or analge sia. Intra-articular analgesia is often used after joint surgery and occasionally in joints with OA. Lidocaine, bupivacaine, ropivacaine and opiates have been evaluated as intra-articular analgesics, mostly for postoperative pain.
14 Botulinum toxin A has been evaluated as a therapy for chronic joint pain and OA. 58 Chondrolysis associated with the use of intra-articular local anaesthetic 'pain pumps' has been described by several groups, 59 -61 which has raised concern about the clinical use of intra-articular anaes thetics. Dose-dependent toxic effects of analgesics, including apoptosis, have been demonstrated in vitro. 62 The type and concentration of anaesthetic, as well as additives and pH, have been implicated in the chondrotoxicity of intra-articular analgesics. 62, 63 Ropivocaine is less toxic in cultured chondrocytes and cartilage explant systems than bupivacaine. 63 Intra-articular drug delivery systems As we have mentioned, low MW compounds are cleared rapidly from the joint space. Furthermore, poor drug solubility and poor tissue distribution within the joint have helped to create interest in designing drug delivery systems specifically for the intra-articular environment. As we discuss here, liposomes and microparticles have consequently been evaluated in the context of intra-articular drug delivery.
Liposomes
Liposomes entrap primarily hydrophobic drugs in a lipid bilayer or lipid phase, and enable sustained release through liposome dissolution and slow solubilization of the drug. Liposome drug-loading efficiencies as high as 90% are possible for many hydrophobic drugs and these vesicles are thus attractive for delivering corticosteroids such as triamcinolone, celocoxib, dexamethasone, and cortisol-21-palmitate. [64] [65] [66] The longevity of the drug and its onset of action are dependent upon particle size, with results suggesting that liposomes can extend drug activity by as much as 14 days. 64 This pharmacodynamic extension might be attributable to efficient endocytosis of the liposome and/or to prolonged drug re-solubilization. Particle sizes of 100 nm-5 μm seem to be suitable for achieving 
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prolonged drug retention, with too rapid clearance of drug from liposomes noted for much smaller particles. 11, 67 Liposomes are less useful with more polar drugs, such as methotrexate, because of low drug loading ratios and a rapid burst release encountered in the aqueous environment of the synovial fluid. 11, 67 Moreover, liposomal prepara tions require mixing of the drug with organic solvents that are damaging to proteinaceous drugs. Nevertheless, several therapeutic liposomal formulations are in clinical use for a variety of indications, including the delivery of doxorubicin in cancer (for example, Doxil TM , Janssen Biotech, Beerse), amphotericin for fungal infection (for example, AmBisome TM , Astellas Pharma, Tokyo) and cytarabine for cancer (Depocyt®, Sigma-tau Pharma, Gaithersburg), with good safety profiles that suggest their potential utility for localized intra-articular delivery. Knowledge of these liposomal formulations applies, however, to intravenous, topical or intramuscular use, with only one liposomal product available for intraarticular delivery, a palmitylated dexamethasone, and only in Germany (Lipotalon®, Merckle, Ulm).
Microparticles and nanoparticles
For proteinaceous drugs and polar molecules, synthetic polymeric microparticles and nanoparticles might be more suitable than liposomes as drug delivery systems for the joint space. Biodegradable microparticles composed of polyesters (for example, PLGA, PLLA), poly anhydrides, and polycaprolactones have been developed for broader clinical applications, including the encapsulation of synthetic hormones (Lupron®, Abbott, Illinois), tretinoin (RetinA Micro®, OrthoNeutrogena, Los Angeles) and risperidone (Riseperdal®, Janssen Pharma, Beerse) and have shown potential for prolonging intra-articular drug residence time in preclinical studies. For betamethasone, 68, 69 methotrexate, 70 diclofenac, 71 siRNA 72 and paclitaxel, 73 for example, encapsulation in microspheres composed of PLLA, PLGA, or polycaprolactones contributed to a sustained release effect in animal models of arthritis that could be observed up to 21 days after delivery in some cases. [68] [69] [70] [71] Drug availability within the joint space after delivery within a microsphere depends on the competing and synergistic processes of drug diffusion from the polymer, erosion of the polymeric microparticle, and size-dependent endocytosis of the particle. As with liposomes, microparticles of a range of sizes can seemingly be endocytosed without provoking deleterious inflammation (generally particles <30 µm), and a lower size limit exists below which little benefit of particulation is noted (50 nm). Drugs have also been studied following encapsulation in naturally derived polymeric ma terials, including chitosan microspheres, albumin, gelatin, e lastin-based systems and collagen. Overall, particle-based delivery systems have the potential to increase drug residence times greatly, with 10-30-fold increases reported in pre-clinical models. A clinical study reported in 2013 of a PLGA-encapsulated corticosteroid, triamcinolone acetonide (FX006, Flexion Therapeutics, Burlington), demonstrated residence in the joint space at thera peutic concentrations at 6 weeks after injection, 74 providing some evidence of even longer periods of sustained release for microcapsules. Nevertheless, no particle-based or liposome drug-delivery system has yet advanced past clinical trials for intra-articular drug delivery in the USA, possibly because of the need to establish cost-effective ma nufacturing processes and dosing strategies.
Modifying drugs to increase dwell time Direct modification of known drugs is a widely used strategy to prolong their residence time in the joint. Conjugation of a PEG moiety to a drug-PEGylation-is a frequently used method to increase the bio availability of hydrophobic drugs and increase their molecular weight towards the goal of delaying systemic elimination. Similarly, a thermally responsive small poly peptide, elastin-like polypeptide (ELP), has been conjugated to protein drugs in a process called ELPylation. 75 ELPylation leads to the temperature-controlled formation of a drug depot at the site of injection that has the potential to decrease drug clearance from the injection site. ELP has been conjugated to multiple drugs (including TNF and IL-1 antagonists) 76, 77 for application to intra-articular or perineural delivery. This approach has the potential to provide a 20-fold increase in intra-articular drug residence time, 78 but is complicated by involving the creation of a novel conjugate, rather than an entrapped drug, with pharmacokinetics and pharmacodynamics that are not thoroughly studied.
Nonsurgical synovectomy with radionuclides
When particles of phagocytosable size are injected into joints they are taken up by macrophages present in the synovium. This process has been used to achieve non surgical synovectomy via the incorporation of radio active materials in small particles, suspensions of which are injected into the joint. The technique is used for chronic synovial conditions, such as diffuse pigmented villo nodular synovitis and the haemorthrosis of patients with haemophilia, that are difficult to treat by other means. Historically a common treatment for RA, radioactive synovectomy has also been evaluated in OA. 79 Improvements in pain and inflammation were noted, with the greatest effects seen in knees with the least radiological evidence of damage. 79 Isotopes of the lanthanide series of elements, such as Y , are particularly suited to this purpose. 80 Although radiation synovectomy is rarely used for OA or RA, it is a method of choice for haemophilic synovitis. 81 Radiation synovectomy is complicated by rare cutaneous radiation necrosis 82 and concerns about genotoxic effects. 83 
Gene therapy
Local gene transfer to the joint provides one solution to the problem of maintaining a sustained, therapeutic concentration of a gene product within a diseased joint, and can be accomplished by administration of cells genetically modified ex vivo 84 or by the direct, intra-articular injection of viral or nonviral vectors. 85 Intra-articular gene therapy-as reviewed in this journal in 2011 86 -has been evaluated in phase I clinical trials in patients with RA and OA. A phase II study in RA, using adeno-associated virus to deliver etanercept, was marred by the death of one of the study participants, but was allowed to proceed to completion. 87 Phase II trials in OA, using allogeneic cells expressing transforming growth factor β 1 , are continuing in Korea and the USA. 86 
Cell-based therapies
The first clinical use of intra-articular cell delivery was in the context of gene therapy, using genetically modified, autologous synovial fibroblasts (Table 2) . 84 Since then, chondrocytes and blood cells have been injected into human joints (Table 2 ), but by far the greatest activity surrounds the use of mesenchymal stem cells (MSCs). Their use has increased spectacularly in the past 3 years: 31 trials are listed in Table 2 ; 23 of them involve MSCs and, of these, 20 were registered on ClinicalTrials.gov from 2010 onwards.
As described by Barry and Murphy in this journal, 88 the potential intra-articular use of MSCs in treating OA has attracted considerable attention because MSCs are thought to be anti-inflammatory and immunosuppressive mediators of tissue regeneration. [89] [90] [91] Encouraging preclinical data have emerged [92] [93] [94] in relation to preventing post-traumatic OA, regenerating damaged cartilaginous surfaces and reducing pain. The intra-articular injection of MSCs derived from bone marrow or fat is widely used in equine medicine for the treatment of OA and such therapies are commercially available for use in animals. Only a few small human clinical case series have been published, such as a study using autologous MSCs in four people with knee OA, 95 with equivocal results. The immunosuppressive nature of MSCs introduces the possibility that they can be successfully allografted, which raises the prospect of developing a therapy from a universal donor; such a step would reduce the cost and complexity of generating approved treatments.
Conclusions
The intra-articular injection of therapeutic agents is an attractive strategy for the local treatment of joint diseases. Most joints are accessible to accurate injection, especially when using image guidance. Given that such injections cannot be administered too frequently, it is preferable to use reagents that have a lasting therapeutic effect. However, soluble agents are rapidly cleared from joints, regardless of the size of the drug, and this transience remains a major barrier to successful therapy. Intra-articular injection became popular in the latter half of the twentieth century owing to the introduction of intra-articular corticosteroids. Today, this treatment and the injection of hyaluronate into joints with OA form the major uses of this technique. Interest in delivering recombinant proteins, autologous blood products, particles, cells and gene therapy vectors to diseased joints con tinues to mount. Local delivery in this fashion is potentially safer, less expensive and more effective than parenteral delivery. Reducing the need for burdensome repeated injections of soluble therapeutics will, however, require better drug formulations with more lasting efficacy.
Review criteria
PubMed served as the primary database to identify relevant articles, initially using the search terms "intra-articular AND therapy" without limiting date of publication. The list of articles was screened by title for articles in English, with a bias towards articles that were recent, clinical and novel. Nonclinical articles were included if they provided mechanistic insight or supplied preclinical advances. The abstracts of the selected articles were then read to identify relevant papers that were down-loaded and studied in detail. More focused searches were then conducted using search terms "intra-articular AND steroid", "intra-articular AND hyaluronan", "intra-articular AND protein", "intraarticular AND cell" and "intra-articular AND osteoarthritis AND therapy". The authors drew on their own expertise in research in the area of intra-articular therapy to identify additional references. www.ClinicalTrials.gov was searched to provide the information given in Tables 1 and 2. 
